한글목차

아리케이스의 성장을 이끄는 주요 요인들

1. 시장 점유율 확대 및 신규 환자 수 증가

• 알리케이세는 비결핵성 항산균(NTM) 폐질환 시장, 특히 표준 치료에 반응하지 않는 난치성 마이코박테리움 아비움 복합체(MAC) 폐질환 환자에서 지속적으로 점유율을 확대하고 있습니다.
• NTM 감염증의 진단율 증가와 의사들의 인식 개선으로 전문 폐질환 센터의 신규 환자 치료 시작이 촉진되고 있습니다.
• Insmed의 의사 교육 및 환자 지원 프로그램을 포함한 집중적인 상업적 전략으로 인해 아리케이스의 세계 채택이 가속화되고 있습니다.

2. 주요 적응증 확대

• 난치성 MAC 폐질환: 아리케이스는 기존의 다제 병용요법에 반응하지 않는 성인 MAC 폐질환 환자들을 위해 승인되었으며, 아미카신을 폐에 직접 전달하는 표적 치료제를 제공합니다.
• 보다 광범위한 NTM 감염 질환: 현재 진행 중인 연구와 실제 임상에서 사용하면서 MAC 이외의 NTM 균종에 대한 적응증 확대 가능성을 모색하고 있습니다.
• 초기 치료 단계에서의 사용 가능성: 파이프라인 및 실제 임상 데이터를 바탕으로 초기 치료 단계 및 병용요법에서 앨리케이스를 평가했습니다.

3. 지역적 확장

• 아리카이스는 미국, 유럽, 일본에서 판매되고 있으며, 다른 세계 시장으로 계속 확장해 나가고 있습니다.
• 아시아태평양은 NTM 유병률 증가, 고령화, 진단 인프라 개선 등을 배경으로 중요한 성장 지역입니다.
• Insmed는 보급 촉진을 위해 지역 파트너십, 상환 전략, 유통 네트워크 강화에 힘쓰고 있습니다.

4. 신규 적응증 승인

• 알리케이세는 난치성 MAC 폐질환에 대해 미국, EU, 일본에서 규제 당국의 승인을 획득했습니다.
• 보건당국은 추가적인 비결핵성 항산균증 환자군에 대한 적응증 확대 가능성을 염두에 두고 적응증 확대 및 시판 후 데이터 검토를 지속하고 있습니다.

5. MAC 폐 질환 분야에서 강력한 사례 수 확대

• MAC 폐질환은 여전히 주요 촉진요인으로 난치성 환자의 처방 건수가 지속적으로 증가하는 추세입니다.
• Insmed의 최신 정보에 따르면 실제 임상에서 좋은 치료 성과와 복약 순응도에 힘입어 처방 건수는 전년 대비 지속적인 증가 추세를 보이고 있습니다.
• 호흡기내과 및 감염내과 전문의의 의뢰 환자 수가 증가하면서 치료 모멘텀이 더욱 강화되고 있습니다.

6. 경쟁 우위 및 시장 동향

• 흡입용 리포좀 제제는 폐내 고농도 약물 유지를 가능하게 하면서 전신 노출을 억제하여 정맥내 투여하는 아미카신과 차별화됩니다.
• 표적 폐 치료는 내약성과 장기 치료의 실현 가능성을 높입니다.
• 정밀한 호흡기 항감염 치료, 외래진료, 리얼월드 증거에 기반한 상환제도에 대한 시장 동향은 알리카세 포지셔닝에 힘을 실어주고 있습니다.
• 실제 증거에 대한 의존도가 높아짐에 따라 지불자의 신뢰성이 강화되고 있습니다.

이 보고서는 비결핵성 항산균 감염과 같은 승인된 적응증과 낭포성 섬유증 관련 호흡기 감염 및 기관지확장증과 같은 잠재적 적응증에 대한 주요 7개국(미국, EU4(독일, 프랑스, 이탈리아, 스페인), 영국)의 아리케이스에 대한 종합적인 인사이트을 제공합니다. 2020-2034년까지 케케묵은 주요 7개국에서 아리케이스의 승인된 적응증 및 잠재적 적응증에 대한 사용 현황, 진입 전망, 성과에 대한 상세한 전망과 함께 승인된 적응증 및 잠재적 적응증에 대한 아리케이스의 상세한 설명을 제공합니다. 또한 이 약물의 매출 예측, 작용기전(MoA), 용량 및 투여방법, 규제 마일스톤을 포함한 연구개발 및 기타 활동에 대한 정보를 제공합니다. 또한 과거 및 현재 아리케이스의 실적, 미래 시장 평가, SWOT 분석, 애널리스트의 견해, 경쟁사 개요, 각 적응증에 대한 다른 신흥 치료제 개요, 매출 예측 분석, 시장 견인 요인 등을 정리했습니다.

목차

제1장 리포트 개요

제2장 아리케이스 개요 : 비결핵성항산균감염증 등의 승인 적응증·낭포성 섬유증 관련 호흡기 감염증 및 기관지확장증 등의 잠재적 적응증

제3장 아리케이스 : 경쟁 구도(출시 치료제)

제4장 경쟁 구도 : 경쟁 구도(개발 후기 치료제)

제5장 아리케이스 : 시장 평가

제6장 아리케이스 : SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight 소개

제12장 리포트 구입 옵션

제1장 보고서의 개요

제2장 아리케이스 비결핵성항산균감염증 등의 승인된 적응증 및 낭포성 섬유증 관련 호흡기 감염증 및 기관지확장증 등의 잠재적 적응증의 개요.

제3장 아리케이스의 경쟁 상황(시판되고 있는 치료법)

제4장 경쟁 구도(후기 단계 신규 아리케이스 요법)

제5장 아리케이스 시장 평가

제6장 아리케이스 SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight 소개

제12장 리포트 구입 옵션

영문목차

Key Factors Driving ARIKAYCE Growth

1. Market Share Gains and New Patient Starts

• ARIKAYCE continues to expand its share in the nontuberculous mycobacterial (NTM) lung disease market, particularly in patients with refractory Mycobacterium avium complex (MAC) lung disease who have failed standard therapy.
• Growing diagnosis rates of NTM infections and rising physician awareness are driving new patient starts across specialty pulmonary centers.
• Insmed's focused commercial strategy, including physician education and patient support programs, is accelerating ARIKAYCE adoption globally.

2. Expansion Across Key Indications

• Refractory MAC Lung Disease: ARIKAYCE is approved for adults with MAC lung disease who do not respond to conventional multidrug therapy, offering targeted delivery of amikacin directly to the lungs.
• Broader NTM Infections: Ongoing research and real-world use are exploring potential expansion into other NTM species beyond MAC.
• Earlier-Line Use Potential: Pipeline and real-world data are supporting evaluation of ARIKAYCE in earlier treatment settings and in combination regimens.

3. Geographic Expansion

• ARIKAYCE is marketed in the United States, Europe, and Japan, with continued expansion into additional global markets.
• Asia-Pacific is a key growth region, driven by increasing NTM prevalence, aging populations, and improved diagnostic infrastructure.
• Insmed is strengthening regional partnerships, reimbursement strategies, and distribution networks to accelerate uptake.

4. New Indication Approvals

• ARIKAYCE received regulatory approvals in the US, EU, and Japan for refractory MAC lung disease.
• Health authorities continue to review label expansions and post-marketing data to potentially broaden its use across additional NTM populations.

5. Strong MAC Lung Disease Volume Momentum

• MAC lung disease remains the primary growth driver, with sustained prescription growth in refractory patients.
• Insmed's recent updates highlight continued year-over-year volume growth, supported by strong real-world outcomes and adherence.
• Increasing referrals from pulmonologists and infectious disease specialists are reinforcing treatment momentum.

6. Competitive Differentiation and Market Trends

• Inhaled liposomal delivery enables high local drug concentrations in the lungs while limiting systemic exposure, differentiating ARIKAYCE from IV amikacin.
• Targeted pulmonary therapy improves tolerability and long-term treatment feasibility.
• Market trends toward precision respiratory anti-infective therapies, outpatient care, and real-world data-driven reimbursement support ARIKAYCE's positioning.
• Growing reliance on real-world evidence (RWE) is strengthening payer confidence.

ARIKAYCE Recent Developments

In October 2024, Insmed Incorporated reported financial results for the third quarter ended September 30, 2024, and provided a business update.

• ARIKAYCE global revenue grew 18% in the third quarter of 2024 compared to the third quarter of 2023, reflecting an all-time revenue high and double-digit year-over-year growth in the US, Japan, and Europe and rest of world.
• Insmed has closed screening of new patients for the ENCORE study and is now expected to exceed its target enrollment of 400 patients with newly diagnosed or recurrent Mycobacterium avium complex (MAC) lung infection who have not started antibiotics.
• The Company is scheduled to meet with the US Food and Drug Administration (FDA) during the fourth quarter to discuss the possibility of an accelerated approval to expand the label for ARIKAYCE to include all patients with MAC lung infection, based on the positive Phase III ARISE trial data. Insmed continues to expect that the full data from the ongoing ENCORE trial will be required for approval.

"ARIKAYCE Sales Forecast, and Market Size Analysis - 2034" report provides comprehensive insights of ARIKAYCE for approved indication like Nontuberculous mycobacterium infections; as well as potential indications like Cystic fibrosis-associated respiratory tract infections and Bronchiectasis. in the 7MM. A detailed picture of ARIKAYCE's existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 -2034 is provided in this report along with a detailed description of the ARIKAYCE for approved and potential indications. The ARIKAYCE market report provides insights about ARIKAYCE's sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current ARIKAYCE performance, future market assessments inclusive of the ARIKAYCE market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of ARIKAYCE sales forecasts, along with factors driving its market.

ARIKAYCE Drug Summary

ARIKAYCE (amikacin liposome inhalation suspension) is a liposomal formulation of the aminoglycoside antibiotic amikacin, indicated in adults with limited or no alternative treatment options for refractory Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial regimen following >=6 months of standard multidrug therapy without culture conversion, and also approved in the EU for non-tuberculous mycobacterial (NTM) lung infections caused by MAC. Delivered via nebulization using the Lamira Nebulizer System (590 mg/8.4 mL once daily), the liposomes (composed of dipalmitoylphosphatidylcholine, cholesterol, and sodium chloride) enable targeted pulmonary delivery with a mass median aerodynamic diameter of ~4.7 μm, facilitating penetration into bacterial biofilms and macrophage phagocytosis where MAC resides; amikacin binds to the 30S ribosomal subunit, inhibiting bacterial protein synthesis and exerting bactericidal activity against intracellular and extracellular MAC while minimizing systemic exposure. Administered chronically with close monitoring for ototoxicity, nephrotoxicity, bronchospasm, and anti-drug antibodies, ARIKAYCE represents an innovative inhaled therapy for this progressive pulmonary infection affecting vulnerable patients. The report provides ARIKAYCE's sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the ARIKAYCE Market Report

The report provides insights into:

• A comprehensive product overview including the ARIKAYCE MoA, description, dosage and administration, research and development activities in approved indications like Nontuberculous mycobacterium infections; as well as potential indications like Cystic fibrosis-associated respiratory tract infections and Bronchiectasis..
• Elaborated details on ARIKAYCE regulatory milestones and other development activities have been provided in ARIKAYCE market report.
• The report also highlights ARIKAYCE's cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
• The ARIKAYCE market report also covers the patents information, generic entry and impact on cost cut.
• The ARIKAYCE market report contains current and forecasted ARIKAYCE sales for approved and potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The ARIKAYCE market report also features the SWOT analysis with analyst views for ARIKAYCE in approved and potential indications.

Methodology:

The ARIKAYCE market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

ARIKAYCE Analytical Perspective by DelveInsight

• In-depth ARIKAYCE Market Assessment

This ARIKAYCE sales market forecast report provides a detailed market assessment of ARIKAYCE for approved indication like Nontuberculous mycobacterium infections; as well as potential indications like Cystic fibrosis-associated respiratory tract infections and Bronchiectasis. in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted ARIKAYCE sales data uptil 2034.

• ARIKAYCE Clinical Assessment

The ARIKAYCE market report provides the clinical trials information of ARIKAYCE for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

ARIKAYCE Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

ARIKAYCE Market Potential & Revenue Forecast

• Projected market size for the ARIKAYCE and its key indications
• Estimated ARIKAYCE sales potential (ARIKAYCE peak sales forecasts)
• ARIKAYCE Pricing strategies and reimbursement landscape

ARIKAYCE Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• ARIKAYCE Market positioning compared to existing treatments
• ARIKAYCE Strengths & weaknesses relative to competitors

ARIKAYCE Regulatory & Commercial Milestones

• ARIKAYCE Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

ARIKAYCE Clinical Differentiation

• ARIKAYCE Efficacy & safety advantages over existing drugs
• ARIKAYCE Unique selling points

ARIKAYCE Market Report Highlights

• In the coming years, the ARIKAYCE market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The ARIKAYCE companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence ARIKAYCE's dominance.
• Other emerging products for Nontuberculous mycobacterium infections; as well as potential indications like Cystic fibrosis-associated respiratory tract infections and Bronchiectasis. are expected to give tough market competition to ARIKAYCE and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of ARIKAYCE in approved and potential indications.
• Analyse ARIKAYCE cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted ARIKAYCE sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of ARIKAYCE in approved and potential indications.

Key Questions:

• What is the class of therapy, route of administration and mechanism of action of ARIKAYCE? How strong is ARIKAYCE's clinical and commercial performance?
• What is ARIKAYCE's clinical trial status in each individual indications such as Nontuberculous mycobacterium infections; as well as potential indications like Cystic fibrosis-associated respiratory tract infections and Bronchiectasis. and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ARIKAYCE Manufacturers?
• What are the key designations that have been granted to ARIKAYCE for approved and potential indications? How are they going to impact ARIKAYCE's penetration in various geographies?
• What is the current and forecasted ARIKAYCE market scenario for approved and potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of ARIKAYCE in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to ARIKAYCE for approved and potential indications?
• Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
• How cost-effective is ARIKAYCE? What is the duration of therapy and what are the geographical variations in cost per patient?

Table of Contents

1. Report Introduction

2. ARIKAYCE Overview in approved indications like Nontuberculous mycobacterium infections; as well as potential indications like Cystic fibrosis-associated respiratory tract infections and Bronchiectasis.

• 2.1. Product Detail
• 2.2. ARIKAYCE Clinical Development
  • 2.2.1. ARIKAYCE Clinical studies
  • 2.2.2. ARIKAYCE Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. ARIKAYCE Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging ARIKAYCE Therapies)

5. ARIKAYCE Market Assessment

• 5.1. ARIKAYCE Market Outlook in approved and potential indications
• 5.2. 7MM Analysis
  • 5.2.1. ARIKAYCE Market Size in the 7MM for approved and potential indications
• 5.3. Country-wise Market Analysis
  • 5.3.1. ARIKAYCE Market Size in the United States for approved and potential indications
  • 5.3.2. ARIKAYCE Market Size in Germany for approved and potential indications
  • 5.3.3. ARIKAYCE Market Size in France for approved and potential indications
  • 5.3.4. ARIKAYCE Market Size in Italy for approved and potential indications
  • 5.3.5. ARIKAYCE Market Size in Spain for approved and potential indications
  • 5.3.6. ARIKAYCE Market Size in the United Kingdom for approved and potential indications
  • 5.3.7. ARIKAYCE Market Size in Japan for approved and potential indications

6. ARIKAYCE SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options